Feature | Heart Valve Technology | July 01, 2015

CardiAQ Valve Technologies Reports First-in-Human Implantation with Second Generation Transcatheter Bioprosthetic Mitral Heart Valve

Self-conforming, self-anchoring device implanted in 72-year-old male with severe mitral regurgitation in Rome

CardiAQ Valve Technologies, TMVI, second generation, implantation, Tor Vergata

July 1, 2015 - CardiAQ Valve Technologies (CardiAQ) announced that its second-generation transcatheter bioprosthetic mitral heart valve was successfully implanted as a compassionate treatment. The device was placed into a 72-year-old male suffering from severe mitral regurgitation (MR 4+) with multiple co-morbidities and ineligible for alternate treatment modalities.

The procedure was performed at the Tor Vergata Hospital in Rome, Italy, by an experienced heart team led by Director of Cardiology Francesco Romeo, M.D., and interventional cardiologist Gian Paolo Ussia, M.D., also including cardiac surgeon Giovanni Ruvolo, M.D., anesthesiologist Pasquale De Vico, M.D., and echocardiographer Valeria Cammalleri, M.D. Interventional cardiologist Lars Sondergaard, M.D., (Rigshospitalet, Copenhagen, Denmark) and cardiovascular surgeon and inventor of the CardiAQ TMVI technology Arshad Quadri, M.D., (St Francis Hospital, Hartford, CT) also participated.

"We have now performed three CardiAQ TMVI [transcatheter mitral valve implantation] cases (2 transapical and 1 transseptal) at Tor Vergata with excellent results, reducing the severe MR to trace and with no mitral or outflow tract gradients," said Ussia, who is primary investigator at the Rome Hospital. "We are convinced that these new procedures will in the future represent a substantial treatment improvement for our patients with mitral valve disease. Our heart team is excited to be a part of these groundbreaking clinical trials."

The CardiAQ device is a self-conforming, self-anchoring technology for nonsurgical transfemoral-transseptal percutaneous TMVI.

For more information: www.cardiaq.com

Related Content

Boston Scientific, Edwards Lifesciences Agree To Global Litigation Settlement
News | Heart Valve Technology | January 15, 2019
Boston Scientific Corp. and Edwards Lifesciences Corp. announced that the companies have reached an agreement to settle...
The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as a arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital. Dr. Dominick Wiktor. The TEE is from a Philips Epiq system.

The implantation of a MitraClip is guided under live transesophageal echo (TEE). This image shows the operator moving the open clip into position and engaging the mitral valve leaflets. The clip appears as an arrowhead shape in the ultrasound with the leaflets coming off each side. Photo from a MitraClip procedure at the University of Colorado Hospital.

Feature | Heart Valve Technology | January 14, 2019 | Allen Atchley, M.D., FACC, The Chattanooga Heart Institute
Mitral regurgitation (MR) is one of the most common types of heart valve diseases in the United States, affecting app
JC Medical Announces First U.S. Treatment With J-Valve TAVR Device
News | Heart Valve Technology | January 07, 2019
January 7, 2019 — JC Medical announced the successful treatment of the first U.S.
Edwards' Sapien 3 Ultra Transcatheter Heart Valve Receives FDA Approval
Technology | Heart Valve Technology | January 02, 2019
Edwards Lifesciences Corp. announced that the Sapien 3 Ultra system has received U.S. Food and Drug Administration (FDA...
Boston Scientific Prevails in U.S. Edwards Lifesciences Litigation
Feature | Heart Valve Technology | December 12, 2018
A jury in the U.S. District Court for the District of Delaware determined Dec. 11 that the Boston Scientific U.S....
First TriCinch Coil Tricuspid Repair Systems Implanted in U.S.
News | Heart Valve Technology | November 06, 2018
4Tech Inc. initiated its U.S. Early Feasibility Study of the TriCinich Coil System following U.S. Food and Drug...
Valve Replacement Volume Key to Successful Patient Outcomes
News | Heart Valve Technology | November 02, 2018
Hospitals that routinely perform a heart valve replacement procedure requiring open heart surgery are more likely to...
Prosthetic Valve Mismatches Common in TAVR Procedures
News | Heart Valve Technology | October 03, 2018
A high number of patients in a study who underwent transcatheter aortic valve replacement (TAVR) experienced severe and...
Local Anesthesia Safe and Effective for Intermediate- and High-Risk TAVR Patients
News | Heart Valve Technology | September 28, 2018
The first randomized study to compare general versus local anesthesia during transcatheter aortic valve replacement (...
Overlay Init